Read #ASCO26 insights from Neeraj Agarwal and Mary‑Ellen Taplin on rPFS benefit in mCSPC and improved MFS in high-risk disease, highlighting advances across the disease continuum https://ow.ly/BVZ750Z8SY5

Watch Bjørn Henning Grønberg discuss the latest insights in extensive‑stage small cell lung cancer from #ASCO26, including why adding thoracic radiotherapy may not improve survival, and what this means for practice Now available on the Medthority YouTube channel https://ow.ly/4pZL50Z7EYp

What’s shaping treatment decisions in lung cancer? Read our short summary articles on key data from #ASCO26, including insights on second-line SCLC strategies and first-line NSCLC approaches from Shun Lu and Tony Mok https://ow.ly/3nWh50Z7uFl

What really matters to patients with bladder cancer? Read key insights from Maria De Santis and Peter O’Donnell at #ASCO26 on preserving quality of life across NMIBC and MIBC, covering the latest data and what this means for practice https://ow.ly/LngY50Z7aQs

📰It's Newsday Tuesday! Catch up on the news you need to know from #ASCO26 with our dedicated congress hub. Don't miss updates on second-line strategies in SCLC, first-line options in NSCLC, and the latest trial data in bladder and prostate cancer https://ow.ly/VgzC50Z6I9F

That wraps our #ASCO2026 coverage. If you missed any updates, head over to Medthority to catch up on expert insights and the highlights you need to know in lung, prostate and bladder cancer #Oncology #MedSky #MedEd ow.ly/27Fb50Z5XgP

Lauren Averett Byers presents: Phase 1 ABBV-706 ± budigalimab in R/R SCLC 📊 • ABBV-706: mOS 14.3 mo in 2L (1.8 mg/kg); ORR up to 82%✅ • Combo shows encouraging antitumor activity + manageable safety Promising activity in heavily pretreated pts #ASCO26 #LungCancer #SCLC #Oncology

DeLLphi-304 post-hoc presented by @drgreeklungcancer.bsky.social: Tarlatamab improves intracranial outcomes vs chemo in 2L SCLC with BM🧠 • CNS PFS 6.5 vs 4.2 mo (HR 0.40)✅ • CNS CR 15% vs 5% • OS 13.9 vs 6.8 mo (HR 0.51)✅ Supports tarlatamab as SOC in 2L #ASCO26 #LungCancer #SCLC #Oncology

Phase III study reported by Bjorn Henning Gronberg: adding TRT to durvalumab + platinum/etoposide in ES-SCLC did not improve outcomes: • OS 10.0 vs 11.1 mo • No PFS or ORR benefit • More SAEs and treatment-related deaths #ASCO26 #LungCancer #SCLC #Oncology #MedEd #MedSky

What emerging strategies could reshape outcomes in small cell lung cancer? Don’t miss our coverage of phase III and novel treatment insights presented by Bjorn Henning Gronberg, Giannis Mountzios MD and Lauren Averett Byers at #ASCO2026. Follow along for live coverage

5-year POTOMAC summary: ✅ No OS detriment ✅ QoL largely preserved ✅ Prior DFS benefit maintained ➡️ Long-term data strengthen durvalumab + BCG in high-risk NMIBC #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

Patient-reported outcomes from POTOMAC: 🔹 No major impact on QoL 🔹 Changes generally small between arms ⚠️ Fatigue ↑ but “not regarded as significant” ➡️ Supports tolerability alongside efficacy #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

5-year POTOMAC update in BCG-naïve, high-risk NMIBC: 🔹 OS HR 0.81 (95% CI 0.54–1.19) 🔹 Median OS not reached ➡️ No detriment to OS with durvalumab + BCG ~72 months follow-up #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

We’re back with more #ASCO26 coverage! Today we kick-off with the latest results from the POTOMAC study presented by Maria de Santis

That’s a wrap on our day 3 coverage of #ASCO2026. Catch up on the latest prostate cancer highlights from this year's congress, visit our dedicated ASCO 2026 hub: ow.ly/27Fb50Z5XgP Tune in tomorrow to hear the latest results of the POTOMAC trial @16:00 BST/10:00 CEST

Dr Kim N Chi shares PLUDO crossover analysis: 177Lu-PSMA-617 vs docetaxel in mCRPC 🔁 • No significant differences in rPFS or OS between sequences • Supports use of both therapies in patients progressing after ARPI #ProstateCancer #ASCO26 #Oncology #MedEd

Dr Fred Saad reports on PSMAddition subgroup analysis: 177Lu PSMA 617 + ADT + ARPI improves rPFS across mHSPC 📈 • Consistent benefit across disease volume and de novo/recurrent subgroups ✅ • Safety and PROs similar across groups #ProstateCancer #ASCO26 #Oncology #MedEd

We’re about to start our live coverage of key abstracts from Kim N. Chi, and Fred Saad, as they discuss new data that explores treatment sequencing and patient subgroups in advanced prostate cancer at #ASCO26

👀Keep an eye out for more real-time updates from #ASCO26 this afternoon, and don’t forget our expert scientific team are bringing you closer to the conversations that matter this weekend with ASCO news articles over on Medthority ow.ly/27Fb50Z5XgP#ASCO26

Ivonescimab + chemo delivers: 📈 OS benefit vs PD-1 inhibitor (HR 0.66; P=0.0017) ✅ Consistent across subgroups incl. PD-L1 ⚖️ Manageable, comparable safety profile Supports a new 1L option in advanced sq-NSCLC #ASCO26 #Oncology #MedEd #MedSky

HARMONi-6 OS update: Ivonescimab + chemotherapy improves survival vs tislelizumab + chemotherapy in 1L advanced sq-NSCLC 📊 📈 Median OS 27.9 vs 23.7 mo (HR 0.66) ✅ Significant OS benefit #ASCO26 #Oncology #MedEd #MedSky

What do overall survival data show in previously untreated advanced squamous #NSCLC? Follow our upcoming coverage of results from the phase 3 HARMONi-6 trial, with Shun Lu #ASCO26 #LungCancer #Oncology #MedEd #MedSky

That wraps up our #ASCO26 coverage of the PROTEUS study. For more key prostate cancer updates from ASCO 2026, visit our dedicated congress hub: https://ow.ly/27Fb50Z5XgP#ASCO26 Coming up soon, we shift to #NSCLC with results from the phase 3 HARMONi-6 trial, presented by Shun Lu

PA + ADT shows durable benefit: 📈 EFS: 57.1 vs 38.4 mo ⏳ Approximately 3-year longer time to next therapy (74.2 vs 41.5 mo) 📉 Reduced risk of distant metastases (HR 0.68) ⚖️ Safety consistent with prior studies #ASCO26 #Oncology #MedEd #MedSky #ProstateCancer

APA + ADT delivers: ✅ 9-fold higher pCR/MRD (8.9% vs 1.0%) 📉 ↓ risk of metastasis/death (HR 0.80) 📈 Improved EFS (HR 0.71), TTST1 & TTDM Supporting a new perioperative standard in high-risk disease #ASCO26 #Oncology #MedEd #MedSky #ProstateCancer

PROTEUS phase 3: 1 year perioperative apalutamide + ADT with radical prostatectomy improves outcomes in high-risk localized/locally advanced prostate cancer 📊 ✅ Higher pCR/MRD 📈 Improved MFS vs ADT alone #ASCO26 #Oncology #MedEd #MedSky #ProstateCancer

We kick off our #ASCO26 #ProstateCancer coverage with Mary-Ellen Taplin presenting the final analysis of the PROTEUS study

🎬 That’s a wrap on NSCLC highlights from #ASCO26 Stay tuned for our LIVE updates in prostate cancer, starting at 19:00 BST/13:00 CEST

#SCLC therapeutics are rapidly evolving. Noemi Reguart outlined emerging platforms like T-cell engagers and ADCs as potentially transformative. 👉“Challenge is how to best combine, how to best sequence, and how to ensure safety for our patients” #LungCancer #Oncology #SCLC #MedEd

Radiotherapy remains a cornerstone in #SCLC, as highlighted by Fiona Hegi-Johnson. Hyperfractionation is standard, and RT + immunotherapy appears safe. 🧠 PCI reduces brain metastases, but its impact on QoL keeps MRI surveillance in focus. #LungCancer #Oncology #SCLC #MedSky #MedEd

Clear overview of current standard of care in #SCLC from Rami Manochakian: • LS-SCLC: durvalumab after chemoRT • ES-SCLC: chemo + IO → maintenance IO ± lurbinectedin • 2L ES-SCLC: tarlatamab now SOC More to come 🔜 #LungCancer #Oncology #SCLC #MedEd #MedSky

What are the latest updates in #SCLC? Follow our coverage of today’s #ASCO26 session with Rami Manochakian, Fiona Hegi-Johnson, Noemi Reguart as they discuss what’s new in the world of SCLC

That’s a wrap for this morning’s coverage of the latest in #MIBC at #ASCO26. Keep an eye out for our roundup of the key topics being discussed in the oral abstract sessions on genitourinary cancer starting at 23:00 BST/ 17:00 CEST

KEYNOTE-905 nuance: bowel and sexual function declined in both arms, reinforcing the known impact of radical cystectomy, while overall HRQoL remained broadly preserved with peri-op EV + pembro. #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

“Not just extending life, but also preserving quality of life.” - Peter H. O’Donnell KEYNOTE-905 showed similar FACT-G, FACT-Bl-Cys, BCI and EQ-5D-5L changes over time with peri-op EV + pembro vs cystectomy alone. #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

KEYNOTE-905: peri-op EV + pembro improved outcomes in cis-ineligible MIBC without meaningful HRQoL decline at 18 wks postsurgery. Important signal as peri-op treatment moves into practice #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

That concludes our live coverage of the RAD-IO study. Next, our #MIBC coverage continues with Peter H. O'Donnell, discussing the latest from the KEYNOTE-905 study #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

RAD-io: multi-stage → single-arm phase II (n=55) after COVID impact. Despite non-randomized design, DFS + OS exceed CRT benchmarks → supports further randomized evaluation. #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

RAD-io outcomes at 12 months: • PFS 83% • DFS 72% • OS 96% ChemoRT + IO shows consistent activity across survival endpoints in localized MIBC. #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

RAD-io feasibility: ✔️ 54/54 completed RT (55 Gy/20 fx) ✔️ 87% on schedule ✔️ 74.5% received neoadjuvant chemo Supports deliverability of CRT + IO in real-world MIBC populations. #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

RAD-io in MIBC: chemoRT + durvalumab achieves 80% DFS at 12 months (40/50 pts) vs ~60% historical benchmark. Signal exceeds pre-set threshold for further study Nick James #ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky

How feasible is combining immunotherapy with chemoradiotherapy in #MIBC? Follow our #ASCO26 coverage for new data from Nick James#MIBC?#ASCO26n the RAD-IO trial #BladderCancer #Oncology #MedEd #MedSky

That’s a wrap on day 1 coverage of #MIBC at #ASCO2026! Come back tomorrow to hear the latest updates from the KEYNOTE study starting at 14:15 BST/08:15 CEST

HRQoL outcomes in high-risk #MIBC after surgery will be presented from the Phase 3 AMBASSADOR trial. Follow our coverage for insights from Ronald C. Chen #BladderCancer #Oncology #MedEd

That’s it for today’s coverage of #LungCancer at #ASCO25. Coming very soon… we’ll be discussing the late results from the AMBASSADOR trial starting at 21:45 BST/15:45 CEST

It’s the first day of #ASCO26! We kick off our coverage with Tony Mok discussing the 7-year update from the phase 3 CROWN study #LungCancer #Oncology #NSCLC #OncTwitter #MedEd #MedSky

#ASCO2026 starts today! Follow us over on X and Bluesky for live coverage and the latest updates in prostate, lung, and bladder cancer. Also, don't forget to catch up on the data you need to know about with our summary articles, coming soon on Medthority 👀 X: https://ow.ly/faFL50Z53Co#ASCO2026

As #LupusAwarenessMonth draws to a close, take a look at our #Rheumatology hub for expert-led, on-demand resources, including ACR 2025 highlights and an HLH/MAS masterclass with Fabrizio de Benedetti https://ow.ly/f5Jf50Z52K2

Watch Eduardo Nobile‑Orazio provide key insights on managing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), covering diagnosis, treatment decisions, and why a patient‑centred approach is essential to improving long‑term outcomes https://ow.ly/iiIJ50Z4eyA

📰 It’s News‑day Tuesday! A commonly used asthma treatment may help improve how some cancers respond to immunotherapy by restoring immune system activity. Plus, researchers have uncovered how tumours can hijack immune cells to evade treatment https://ow.ly/S0zI50Z4bEp